A Medicare patient sits in my clinic and asks about weight-loss options. They have heard about the new medications. They know the names. The conversation always stops at the cost. Until recently, I had to explain that standard Medicare coverage for obesity medications was essentially non-existent. The out-of-pocket costs put these treatments out of reach for most of my patients. That conversation changed in late April 2026. CMS updated its coverage rules and built a functional pathway for specific GLP-1 therapies, including the newly approved oral option, Foundayo. The cost is capped, and the rules are clear. In this blog post, we will discuss what CMS announced, why Foundayo on the formulary is the headline, and the three documentation moves you must make this week to put the program to work in your clinic.
What CMS announced
Between April 21 and April 27, 2026, CMS confirmed an essential update to its GLP-1 Bridge Model. The agency extended the program through the end of 2027. This [extension](https://www.usnews.com/news/health-news/articles/2026-04-27/cms-extends-medicares-short-term-bridge-program-for-glp-1-obesity-drug-coverage) removes the uncertainty that surrounded the initial pilot phase. The program guarantees a $50 per month out-of-pocket maximum for eligible Medicare beneficiaries. The [official announcement](https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries) detailed the structure. The formulary is specific, such as Wegovy, Zepbound, and Foundayo for the obesity indication. However, this extension happened while CMS simultaneously shelved the BALANCE Model. The BALANCE proposal would have introduced broader payment redesign for obesity care. With BALANCE on hold, the Bridge program is the only coverage mechanism available for this specific patient population. You have a clear runway through 2027 to use it.
Why Foundayo on the formulary is the headline
The inclusion of Foundayo on the Bridge formulary changes how I practice. Foundayo is orforglipron, an oral non-peptide GLP-1 receptor agonist. The [FDA approved Foundayo](https://www.statnews.com/2026/04/01/eli-lilly-obesity-pill-approved-orforglipron-foundayo/) on April 1, 2026. The [labeling data](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill) confirms it is a daily pill for weight management. Undoubtedly, many patients will not take an injection. The barrier is absolute. Having an oral option on a Medicare formulary means I can treat a segment of my panel that was previously inaccessible. The sequence of treatment also matters. The [ATTAIN-MAINTAIN trial](https://www.pharmacytimes.com/view/orforglipron-shows-strong-weight-maintenance-in-phase-3-attain-maintain-trial) showed that patients switching from semaglutide to orforglipron saw a 5 percent weight regain, while patients switching from tirzepatide saw a 20 percent regain. The [peer-reviewed ATTAIN-2 data](https://www.nejm.org/doi/abs/10.1056/NEJMoa2505669) supports the efficacy profile. I can start a patient on an injectable for initial reduction and transition them to the oral option for maintenance, knowing the coverage will support the switch.
The three documentation moves every physician should make this week
The $50 price point is only available if your chart notes are clean. The program requires strict adherence to the FDA-labeled indications. I focus on three specific moves for every potential patient. 1. **Capture the exact BMI.** The patient must have a BMI of 30 or higher. If the BMI is between 27 and 29.9, you must document a weight-related comorbidity. I record height and weight manually at the index visit. I do not rely on previous records. 2. **Code the comorbidities explicitly.** If you are using the lower BMI threshold, you must list the specific diagnosis codes, such as hypertension or dyslipidemia. You must write a sentence connecting the weight-management plan to the control of that specific comorbidity. 3. **Complete the contraindication screen.** Every note must include a statement confirming a negative personal and family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. A missing screen will result in an immediate prior-authorization denial. If you build these three habits into your clinic workflow this week, you can rest assured that the first round of prior-authorization requests will move quickly.
Who doesn’t qualify? What to say to those patients.
The rules are rigid. Patients with type 2 diabetes are excluded from the Bridge program for obesity management. They must use their standard Part D coverage pathways. I explain this clearly. The diagnosis dictates the coverage channel. Patients with a BMI below 27 do not qualify under any circumstance. The conversation here focuses on lifestyle modification. I tell them the medication is not approved for their weight class and the program will not cover it. Patients with active malignancies also face an uphill battle for coverage due to the lack of safety data. I explain the clinical rationale for withholding the prescription. Documenting the specific reason for exclusion protects the clinic and creates a clear record of the decision.
Practical Clinical Implementation of the Bridge Model
I am running a specific workflow for this. I pull a list of all Medicare patients with a BMI over 30 who do not have a diabetes diagnosis. I flag their charts for the next visit. I use a dedicated dot-phrase template for these encounters. The template forces me to record the current BMI, check the boxes for lifestyle counseling, and attest to the negative MTC and MEN 2 history. The conversation with the patient is direct. I explain the $50 program. I discuss the options, such as the high weight loss of Zepbound, the cardiovascular data of Wegovy, or the oral convenience of Foundayo. We choose the drug, and the standardized note ensures the prior authorization goes through on the first attempt.
Conclusion
Yes, the Bridge extension is a real opportunity, but it requires precise execution. The program runs through 2027, and CMS will audit the data to decide its future. Your charting today determines the long-term viability of this coverage. The full 2,500-word physician guide, with the chart-template checklist, the BMI/comorbidity decision tree, and the 2027 reassessment-survival section, is on ZayedMD: [Medicare’s $50 GLP-1 Bridge: What Physicians Need to Document for Foundayo, Wegovy, and Zepbound](https://zayedmd.com/blog/medicare-glp1-bridge-foundayo-documentation-2026/).
Licensed physician and clinical AI specialist. Founder and Editor-in-Chief of ZayedMD, a physician-led medical publication covering clinical AI, neurology, metabolic health, and evidence-based patient guidance.
